MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2015 Medtech Predictions

2015 Medtech Predictions
What's in store for the medtech industry this year? Share your predictions.

What's in store for the medtech industry this year? Share your predictions.

When the calendar turns over to a new year, everyone gets out their crystal ball in an attempt to predict what the next 12 months will bring. Here on MD+DI, we've already looked at Cleveland Clinic's top innovations in 2015,  5 medical technologies to watch in 2015, top health industry issues for the year, and top issues and trends expected to shape life sciences over the coming months. 

But here are a few more prognostications we've heard:

With bipartisan support and the change in the balance of power in Congress, we should see the [medical device tax] repealed in 2015."

—Andrew Dallas, MD+DI editorial advisory board member and founder of Full Spectrum Software

Tools that significantly improve the accuracy and allow longer read lengths for next-generation sequencing systems will become available in 2015. These tools will provide researchers with the ability to pioneer completely new diagnostic applications that are currently unattainable and hasten next-generation sequencing into mainstream diagnostic testing.

New entries in the infectious disease market will come out with automated, sample preparation systems that are an order of magnitude cheaper than current systems. Given the recent major shift in healthcare payer strategies, these new products will quickly begin to put pressure on the existing market leaders.

The recent wave of new “checkpoint inhibitor” cancer drugs will open up large new market opportunities for biomarkers and companion diagnostics, and revitalize interest in the immune system for new diagnostic platforms."

—Bill Colston, CEO of HealthTell

Drug-eluting balloons (DEB) is the next big thing in vascular Interventions. The capability to treat both coronary and peripheral indications expands the market. With the first FDA approval in 2014, the global market for this product is likely to double in the next few years. C.R Bard received approval for its Lutonix 035, with Medtronic and others to soon follow suit. It is anticipated that the global DEB market could be worth $600 million to 700 million by 2018 or 2019."

—Sowmya Rajagopalan, Frost & Sullivan Advanced Medical Technologies Research Manager

There will be increasing pressure on hospitals to generate data and analysis that drives understanding of cost, quality and outcomes. 

—John Freund, CEO of Jump Technologies

What do you think the year will bring for medtech? Share your medtech predictions below, and we'll publish our favorites.


Jamie Hartford is MD+DI's managing editor. Reach her at [email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.